Moomoo AI 已提取核心信息
CRISPR Therapeutics, a leading gene editing company, has announced a registered direct offering of 3,916,082 common shares. The shares are offered at an issue price of $71.50 each, with the Nasdaq Global Market listing under the symbol 'CRSP.' The offering is expected to close on or about February 27, 2024, with T+9 settlement. CRISPR Therapeutics intends to use the net proceeds for general corporate purposes, including research and clinical development, manufacturing infrastructure, and working capital. The offering is made pursuant to a prospectus supplement filed with the SEC and is subject to customary closing conditions.
CRISPR Therapeutics, a leading gene editing company, has announced a registered direct offering of 3,916,082 common shares. The shares are offered at an issue price of $71.50 each, with the Nasdaq Global Market listing under the symbol 'CRSP.' The offering is expected to close on or about February 27, 2024, with T+9 settlement. CRISPR Therapeutics intends to use the net proceeds for general corporate purposes, including research and clinical development, manufacturing infrastructure, and working capital. The offering is made pursuant to a prospectus supplement filed with the SEC and is subject to customary closing conditions.
领先的基因编辑公司CRISPR Therapeutics宣布注册直接发行3,916,082股普通股。这些股票的发行价格为每股71.50美元，在纳斯达克全球市场上市，股票代码为 “CRSP”。此次发行预计将于2024年2月27日左右结束，并以T+9结算。CRISPR Therapeutics打算将净收益用于一般公司用途，包括研究和临床开发、制造基础设施和营运资金。此次发行是根据向美国证券交易委员会提交的招股说明书补充文件进行的，并受惯例成交条件的约束。
领先的基因编辑公司CRISPR Therapeutics宣布注册直接发行3,916,082股普通股。这些股票的发行价格为每股71.50美元，在纳斯达克全球市场上市，股票代码为 “CRSP”。此次发行预计将于2024年2月27日左右结束，并以T+9结算。CRISPR Therapeutics打算将净收益用于一般公司用途，包括研究和临床开发、制造基础设施和营运资金。此次发行是根据向美国证券交易委员会提交的招股说明书补充文件进行的，并受惯例成交条件的约束。
有用
没用